UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.